NCT03816332View on ClinicalTrials.gov

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 8, 2019

Primary Completion Date

October 11, 2022

Study Completion Date

September 19, 2026

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Metastatic Basal Cell CarcinomaMetastatic MelanomaMetastatic Merkel Cell CarcinomaMetastatic Skin Squamous Cell CarcinomaPathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Unresectable Basal Cell CarcinomaUnresectable MelanomaUnresectable Merkel Cell Carcinoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Prednisone

Given PO

DRUG

Tacrolimus

Given PO

Trial Locations (7)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

33612

Moffitt Cancer Center - McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

60611

Northwestern University, Chicago

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH